The mechanism of action of Eprileptal and Finasteride is the same, but due to the differences in body type, the therapeutic effect is also different, so the efficacy of the two is not comparable. EPLIX and Finasteride are both type II 5α-reductase inhibitors, whose mechanism of action is to inhibit the conversion of testosterone to dihydrotestosterone and reduce the content of dihydrotestosterone in the prostate gland, resulting in atrophy of the hyperplastic prostate gland, treating benign prostatic hyperplasia and improving the associated clinical symptoms such as urinary frequency, urgency, dysuria, etc. The two drugs have the same pharmacological mechanism of action, but due to the differences in physical condition, their therapeutic effects are not comparable. The two drugs have the same pharmacological mechanism of action, but due to differences in body constitution, sensitivity to the drug is not the same, and the therapeutic effect is also different, so the efficacy of Epagliflozin and Finasteride is not comparable. Adverse reactions such as impotence, decreased libido, ejaculatory disorders, breast enlargement, breast pain and rash may occur with Finasteride. Adverse reactions such as nausea, loss of appetite, bloating, diarrhea, dry mouth, dizziness, insomnia, general malaise, rash, decreased libido, erectile dysfunction, decreased ejaculate volume, tinnitus, ear congestion, and hip pain may occur with Eprileptal. It is contraindicated in those who are allergic to it. The use of Eprileptal with Finasteride needs to be diagnosed by a physician, and the drug should be used reasonably under the guidance of the physician to avoid adverse situations.